布地奈德雾化治疗在COPD急性加重期的应用

目的　观察布地奈德雾化治疗在慢性阻塞性肺病 (COPD)急性加重期的临床疗效。方法　 60例COPD急性加重期住院患者随机分为 3组 ,分别给予布地奈德雾化治疗、泼尼松龙口服和空白对照治疗。观察 3组患者在第 2 4、72小时和第 7天的临床表现、肺功能和动脉血气变化以及副作用情况。结果　布地奈德组和泼尼松龙组的呼吸困难评分、FEV1 和动脉血气的改善程度均明显优于空白对照组 ,而布地奈德组和泼尼松龙组间无显著性差异。布地奈德组的副作用明显少于泼尼松龙组 ,与空白对照组相仿。结论　布地奈德雾化治疗是COPD急性加重期激素治疗的有效选择。

NEBULIZED BUDESONIDE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Objective: To evaluate the effect of Nebulized Budesonide(NB) in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods: 60 patients with acute exacerbations of COPD in the stage Ⅱ were divided into 3 groups in random. The dyspnea score,postbronchodilator FEV_1,arterial blood gases analysis in H_0,H_ 24 ,H_ 72 ,D_7 were measured. And the adverse effect was evaluated at the same time. Results: The changes in postbronchodilator FEV_1,dyspnea score,PaCO_2 in the patients with active treatments were greater than those with placebo. The difference between NB and prednisolone group was no significant. Budesonide had less systemic activity than prednisolone as the placebo. Conclusion: Both NB and prednisolone improved airflow obstruction in COPD patients with acute exacerbations when compared with placebo. NB may be an alternative to oral prednisolone in the treatment of exacerbations of COPD.